Retatrutide 20MG

Retatrutide 20MG

Retatrutide (also known as LY3437943) is a synthetic triple-hormone receptor agonist peptide under active clinical development by Eli Lilly and Company.
It targets GLP-1, GIP, and glucagon receptors simultaneously. This product, typically supplied in a 20 mg lyophilized vial for reconstitution, is sold
exclusively for laboratory and preclinical research purposes in accredited scientific institutions, qualified academic laboratories, or approved research settings.
It is not approved for human use, diagnostic purposes, therapeutic applications, or consumption by humans or animals.

Research Context

Retatrutide is a first-in-class triple agonist designed to modulate multiple metabolic pathways for potential treatment of obesity, type 2 diabetes, and related
conditions. It builds on the success of dual agonists (e.g., tirzepatide) by adding glucagon receptor activation, which may enhance energy expenditure, fat
metabolism, and weight loss beyond GLP-1/GIP mechanisms alone.

As of February 2026, retatrutide remains investigational and is not FDA-approved or available as a prescription medication anywhere in the world. It is in Phase 3
clinical trials (the TRIUMPH program), with multiple ongoing studies evaluating its efficacy and safety in obesity, type 2 diabetes, cardiovascular outcomes, and
complications like knee osteoarthritis.

Current Research Overview (as of 2026)

• Phase 2 trials (e.g., published in NEJM 2023) showed substantial weight loss: up to ~24.2% body weight reduction at 48 weeks with the 12 mg dose in adults with obesity.
• In the first successful Phase 3 trial (TRIUMPH-4, topline results December 2025), participants with obesity/overweight and knee osteoarthritis achieved up to 28.7%
  average body weight loss (≈71.2 lbs) at 68 weeks on the 12 mg dose, plus significant reductions in pain and improvements in physical function. Some participants
  discontinued due to perceived excessive weight loss or related concerns.
• Additional Phase 3 readouts from seven more TRIUMPH trials (in obesity, diabetes, and related indications) are expected throughout 2026.
• Potential benefits under investigation include:
• Superior weight loss compared to current GLP-1/GIP agonists
• Improved glycemic control (reduced HbA1c, better insulin sensitivity)
• Favorable effects on lipid profiles, liver fat, and cardiometabolic risk factors
• Once-weekly subcutaneous administration

Key Research Focus Areas (Updated Status)

Important Notes

• Clinical trial doses have typically escalated to 4 mg, 8 mg, 9 mg, or 12 mg weekly (not 20 mg as a single dose). The 20 mg vial format is common for research
  reconstitution and in vitro/in vivo studies, not reflective of human therapeutic dosing.
• Research must strictly comply with institutional, local, and international regulations for handling investigational peptides, including proper storage (typically
  refrigerated or frozen lyophilized), reconstitution protocols, animal welfare standards (if applicable), and waste disposal.
• Off-target effects, long-term safety, and drug interactions require thorough evaluation.
• For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic purposes. The supplier assumes no liability for misuse outside controlled
  research environments. Counterfeit or unverified sources of retatrutide are circulating online—only obtain from reputable, third-party-tested vendors for legitimate research.

For research use only. Not for human or animal consumption. This product is intended solely for use in accredited academic research facilities and
accredited scientific investigations. The supplier/manufacturer assumes no responsibility for the safe and appropriate use of this compound outside of designated
research environments. Always follow all applicable regulations and guidelines specific to your institution regarding the handling, storage, and disposal of
research chemicals.